Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: A phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study

Circulation

Volumn 128, Issue 5, 2013, Pages 502-511

  Bonderman, Diana ^a   Ghio, Stefano ^b   Felix, Stephan B ^c   Ghofrani, Hossein Ardeschir ^d   Michelakis, Evangelos ^e   Mitrovic, Veselin ^f   Oudiz, Ronald J ^g   Boateng, Francis ^h   Scalise, Andrea Viviana ⁱ   Roessig, Lothar ^j   Semigran, Marc J ^k  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^d JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

^e UNIVERSITY OF ALBERTA   (Canada)

^f KERCKHOFF HEART CENTER   (Germany)

^g UCLA MEDICAL CENTER   (United States)

^h AT Kearney   (United States)

ⁱ Bayer Hispania   (Spain)

^j BAYER PHARMA AG   (Germany)

^k MASSACHUSETTS GENERAL HOSPITAL   (United States)

more..

Author keywords

clinical trial; heart failure, systolic; hypertension, pulmonary; riociguat; soluble guanylate cyclase

Indexed keywords

PLACEBO; RIOCIGUAT;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CARDIOPULMONARY HEMODYNAMICS; CAUSE OF DEATH; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; FAINTNESS; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEART ARREST; HEART CATHETERIZATION; HEART FAILURE; HEART INDEX; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART RATE; HEART RIGHT ATRIUM PRESSURE; HEART STROKE VOLUME; HEART TRANSPLANTATION; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPOTENSION; HYPOXIC ISCHEMIC ENCEPHALOPATHY; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MINNESOTA LIVING WITH HEART FAILURE SCORE; MULTICENTER STUDY; NAUSEA; NEW YORK HEART ASSOCIATION CLASS; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; POLYNEUROPATHY; PRIORITY JOURNAL; PULMONARY ARTERY OCCLUSION PRESSURE; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SYSTEMIC VASCULAR RESISTANCE; THERAPY EFFECT; TREATMENT DURATION; VENOUS OXYGEN TENSION;

CLINICAL TRIAL; HEART FAILURE, SYSTOLIC; HYPERTENSION, PULMONARY; RIOCIGUAT; SOLUBLE GUANYLATE CYCLASE;

ADULT; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; PYRAZOLES; PYRIMIDINES; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84881102246     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.113.001458     Document Type: Article

References (30)

1. Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, Gomez-Sanchez MA, Jondeau G, Klepetko W, Opitz C, Peacock A, Rubin L, Zellweger M, Simonneau G. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2009;34:1219-1263.
2. Califf RM, Adams KF, McKenna WJ, Gheorghiade M, Uretsky BF, McNulty SE, Darius H, Schulman K, Zannad F, Handberg-Thurmond E, Harrell FE Jr, Wheeler W, Soler-Soler J, Swedberg K. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). Am Heart J. 1997;134:44-54.
3. Kalra PR, Moon JC, Coats AJ. Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure? Int J Cardiol. 2002;85:195-197.
4. Lewis GD, Shah R, Shahzad K, Camuso JM, Pappagianopoulos PP, Hung J, Tawakol A, Gerszten RE, Systrom DM, Bloch KD, Semigran MJ. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation. 2007;116:1555-1562.
5. Mulder P, Richard V, Derumeaux G, Hogie M, Henry JP, Lallemand F, Compagnon P, Macé B, Comoy E, Letac B, Thuillez C. Role of endogenous endothelin in chronic heart failure: Effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling. Circulation. 1997;96:1976-1982.
6. Schermuly RT, Janssen W, Weissmann N, Stasch JP, Grimminger F, Ghofrani HA. Riociguat for the treatment of pulmonary hypertension. Expert Opin Investig Drugs. 2011;20:567-576.
7. Katz SD, Hryniewicz K, Hriljac I, Balidemaj K, Dimayuga C, Hudaihed A, Yasskiy A. Vascular endothelial dysfunction and mortality risk in patients with chronic heart failure. Circulation. 2005;111:310-314.
8. Mathier MA, Rose GA, Fifer MA, Miyamoto MI, Dinsmore RE, Castaño HH, Dec GW, Palacios IF, Semigran MJ. Coronary endothelial dysfunction in patients with acute-onset idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 1998;32:216-224.
9. Grimminger F, Weimann G, Frey R, Voswinckel R, Thamm M, Bölkow D, Weissmann N, Mück W, Unger S, Wensing G, Schermuly RT, Ghofrani HA. First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension. Eur Respir J. 2009;33:785-792.
10. Stasch JP, Pacher P, Evgenov OV. Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation. 2011;123:2263-2273.
11. Mitrovic V, Swidnicki B, Ghofrani A, Mück W, Kirschbaum N, Mittendorf J, Stasch JP, Wensing G, Frey R, Lentini S. Acute hemodynamic response to single oral doses of BAY 60-4552, a soluble guanylate cyclase stimulator, in patients with biventricular hear failure. BMC Pharmacol. 2009;9(suppl 1):P51.
12. Ghio S, Bonderman D, Felix SB, Ghofrani HA, Michelakis ED, Mitrovic V, Oudiz RJ, Frey R, Roessig L, Semigran MJ. Left Ventricular Systolic Dysfunction Associated With Pulmonary Hypertension Riociguat Trial (LEPHT): Rationale and design. Eur J Heart Fail. 2012;14:946-953.
13. Grossman W. Grossman's Cardiac Catheterization, Angiography, and Intervention. 6th ed. Philadelphia, PA: Lippincott, Williams and Wilkins; 2000.
14. Douglas PS, DeCara JM, Devereux RB, Duckworth S, Gardin JM, Jaber WA, Morehead AJ, Oh JK, Picard MH, Solomon SD, Wei K, Weissman NJ; American Society of Echocardiography Standards; American College of Cardiology Foundation. Echocardiographic imaging in clinical trials: American Society of Echocardiography standards for echocardiography core laboratories: Endorsed by the American College of Cardiology Foundation. J Am Soc Echocardiogr. 2009;22:755-765.
15. Butler J, Chomsky DB, Wilson Jr. Pulmonary hypertension and exercise intolerance in patients with heart failure. J Am Coll Cardiol. 1999;34:1802-1806.
16. Cappola TP, Felker GM, Kao WH, Hare JM, Baughman KL, Kasper EK. Pulmonary hypertension and risk of death in cardiomyopathy: Patients with myocarditis are at higher risk. Circulation. 2002;105:1663-1668.
17. Damy T, Goode KM, Kallvikbacka-Bennett A, Lewinter C, Hobkirk J, Nikitin NP, Dubois-Randé JL, Hittinger L, Clark AL, Cleland JG. Determinants and prognostic value of pulmonary arterial pressure in patients with chronic heart failure. Eur Heart J. 2010;31:2280-2290.
18. Rich S, McLaughlin VV. Endothelin receptor blockers in cardiovascular disease. Circulation. 2003;108:2184-2190.
19. Guazzi M, Vicenzi M, Arena R, Guazzi MD. Pulmonary hypertension in heart failure with preserved ejection fraction: A target of phosphodiesterase-5 inhibition in a 1-year study. Circulation. 2011;124:164-174.
20. Stasch JP, Pacher P, Evgenov OV. Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation. 2011;123:2263-2273.
21. Abramson SV, Burke JF, Kelly JJ Jr, Kitchen JG 3rd, Dougherty MJ, Yih DF, McGeehin FC 3rd, Shuck JW, Phiambolis TP. Pulmonary hypertension predicts mortality and morbidity in patients with dilated cardiomyopathy. Ann Intern Med. 1992;116:888-895.
22. Ghio S, Gavazzi A, Campana C, Inserra C, Klersy C, Sebastiani R, Arbustini E, Recusani F, Tavazzi L. Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. J Am Coll Cardiol. 2001;37:183-188.
23. Grigioni F, Potena L, Galiè N, Fallani F, Bigliardi M, Coccolo F, Magnani G, Manes A, Barbieri A, Fucili A, Magelli C, Branzi A. Prognostic implications of serial assessments of pulmonary hypertension in severe chronic heart failure. J Heart Lung Transplant. 2006;25:1241-1246.
24. Kjaergaard J, Akkan D, Iversen KK, Kjoller E, Køber L, Torp-Pedersen C, Hassager C. Prognostic importance of pulmonary hypertension in patients with heart failure. Am J Cardiol. 2007;99:1146-1150.
25. Loh E, Stamler JS, Hare JM, Loscalzo J, Colucci WS. Cardiovascular effects of inhaled nitric oxide in patients with left ventricular dysfunction. Circulation. 1994;90:2780-2785.
26. Michelakis E, Tymchak W, Lien D, Webster L, Hashimoto K, Archer S. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: Comparison with inhaled nitric oxide. Circulation. 2002;105:2398-2403.
27. Balik M, Pachl J, Hendl J, Martin B, Jan P, Jan H. Effect of the degree of tricuspid regurgitation on cardiac output measurements by thermodilution. Intensive Care Med. 2002;28:1117-1121.
28. Drazner MH, Thompson B, Rosenberg PB, Kaiser PA, Boehrer JD, Baldwin BJ, Dries DL, Yancy CW. Comparison of impedance cardiography with invasive hemodynamic measurements in patients with heart failure secondary to ischemic or nonischemic cardiomyopathy. Am J Cardiol. 2002;89:993-995.
29. Lewis GD, Murphy RM, Shah RV, Pappagianopoulos PP, Malhotra R, Bloch KD, Systrom DM, Semigran MJ. Pulmonary vascular response patterns during exercise in left ventricular systolic dysfunction predict exercise capacity and outcomes. Circ Heart Fail. 2011;4:276-285.
30. Naeije R. Pulmonary vascular resistance: A meaningless variable. In: Hedenstierna G, Brochard L, Mancebo J, Pinsky MR, eds. Applied Physiology in Intensive Care Medicine. Berlin, Germany: Springer Verlag; 2009:65-68.